NeoGenomics(NASDAQ:NEO) announced the earnings results for Fiscal Year 2016 and Q4. The results came in during Pre-Market on Feb 22, 2017. Based on the corporate Earnings and Guidance, many Investment Banking firms balance their portfolio to Sell and Buy Stocks based on their strategy of investing in stocks.Company reported revenue of $60.490M. Analysts estimated a revenue of $61.830M. The revenues were -2.17% below the estimates. Earnings per share were $0.05. The reported EPS was above estimates by 66.67%. Analysts had estimated an EPS of $0.03.
In a different note, Cantor Fitzgerald said it Initiates Coverage On NeoGenomics, according to a research note issued on Dec 15, 2016. In the research note, the firm Announces the price-target to $11 per share. The shares have been rated ‘Overweight’ by the firm.
NeoGenomics (NEO) made into the market gainers list on Wednesdays trading session with the shares advancing 3.67% or 0.29 points. Due to strong positive momentum, the stock ended at $8.19, which is also near the day’s high of $8.3. The stock began the session at $7.92 and the volume stood at 7,53,751 shares. The 52-week high of the shares is $9.879 and the 52 week low is $5.77. The company has a current market capitalization of $643 M and it has 7,85,12,921 shares in outstanding.
Several Insider Transactions has been reported to the SEC. On Sep 27, 2016, Maher Albitar (Chief Medical Officer) sold 2,800 shares at $8.40 per share price.Also, On May 27, 2016, Oort Douglas M Van (Chairman and CEO) sold 481,387 shares at $8.72 per share price.On May 20, 2016, Steven A Ross (CIO) sold 18,000 shares at $8.50 per share price, according to the Form-4 filing with the securities and exchange commission.
NeoGenomics Inc. is an operator of a network of cancer-focused genetic testing laboratories. The Company offers testing services which includes Cytogenetics testing which is the study of normal and abnormal chromosomes and their relationship to disease; fluorescence in-situ hybridization (FISH) testing which is a branch of cancer genetics that focuses on detecting and locating the presence or absence of specific deoxyribonucleic acid (DNA) sequences and genes on chromosomes; flow cytometry testing which is a way to measure the characteristics of cell populations; immunohistochemistry (IHC) testing which is a process of identifying cell proteins in a tissue section utilizing the principle of antibodies binding specifically to in biological tissues. and molecular testing which is a cancer diagnostic tool focusing on the analysis of DNA and ribonucleic acid (RNA) as well as the structure and function of genes at a molecular level.